Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies.
The lymphocyte-specific transcription factor Interferon (IFN) Regulatory Factor 4 (IRF4) is implicated in certain types of lymphoid and myeloid malignancies. However, the molecular mechanisms underlying its interactions with these malignancies are largely unknown. In this study, we have first profil...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4160201?pdf=render |
| _version_ | 1818997585078124544 |
|---|---|
| author | Ling Wang Zhi Q Yao Jonathan P Moorman Yanji Xu Shunbin Ning |
| author_facet | Ling Wang Zhi Q Yao Jonathan P Moorman Yanji Xu Shunbin Ning |
| author_sort | Ling Wang |
| collection | DOAJ |
| description | The lymphocyte-specific transcription factor Interferon (IFN) Regulatory Factor 4 (IRF4) is implicated in certain types of lymphoid and myeloid malignancies. However, the molecular mechanisms underlying its interactions with these malignancies are largely unknown. In this study, we have first profiled molecular signatures associated with IRF4 expression in associated cancers, by analyzing existing gene expression profiling datasets. Our results show that IRF4 is overexpressed in melanoma, in addition to previously reported contexts including leukemia, myeloma, and lymphoma, and that IRF4 is associated with a unique gene expression pattern in each context. A pool of important genes involved in B-cell development, oncogenesis, cell cycle regulation, and cell death including BATF, LIMD1, CFLAR, PIM2, and CCND2 are common signatures associated with IRF4 in non-Hodgkin B cell lymphomas. We confirmed the correlation of IRF4 with LIMD1 and CFLAR in a panel of cell lines derived from lymphomas. Moreover, we profiled the IRF4 transcriptome in the context of EBV latent infection, and confirmed several genes including IFI27, IFI44, GBP1, and ARHGAP18, as well as CFLAR as novel targets for IRF4. These results provide valuable information for understanding the IRF4 regulatory network, and improve our knowledge of the unique roles of IRF4 in different hematological malignancies. |
| first_indexed | 2024-12-20T21:47:58Z |
| format | Article |
| id | doaj.art-90e16643f73d498396659a80f64caa3a |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-20T21:47:58Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-90e16643f73d498396659a80f64caa3a2022-12-21T19:25:38ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0199e10678810.1371/journal.pone.0106788Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies.Ling WangZhi Q YaoJonathan P MoormanYanji XuShunbin NingThe lymphocyte-specific transcription factor Interferon (IFN) Regulatory Factor 4 (IRF4) is implicated in certain types of lymphoid and myeloid malignancies. However, the molecular mechanisms underlying its interactions with these malignancies are largely unknown. In this study, we have first profiled molecular signatures associated with IRF4 expression in associated cancers, by analyzing existing gene expression profiling datasets. Our results show that IRF4 is overexpressed in melanoma, in addition to previously reported contexts including leukemia, myeloma, and lymphoma, and that IRF4 is associated with a unique gene expression pattern in each context. A pool of important genes involved in B-cell development, oncogenesis, cell cycle regulation, and cell death including BATF, LIMD1, CFLAR, PIM2, and CCND2 are common signatures associated with IRF4 in non-Hodgkin B cell lymphomas. We confirmed the correlation of IRF4 with LIMD1 and CFLAR in a panel of cell lines derived from lymphomas. Moreover, we profiled the IRF4 transcriptome in the context of EBV latent infection, and confirmed several genes including IFI27, IFI44, GBP1, and ARHGAP18, as well as CFLAR as novel targets for IRF4. These results provide valuable information for understanding the IRF4 regulatory network, and improve our knowledge of the unique roles of IRF4 in different hematological malignancies.http://europepmc.org/articles/PMC4160201?pdf=render |
| spellingShingle | Ling Wang Zhi Q Yao Jonathan P Moorman Yanji Xu Shunbin Ning Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies. PLoS ONE |
| title | Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies. |
| title_full | Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies. |
| title_fullStr | Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies. |
| title_full_unstemmed | Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies. |
| title_short | Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies. |
| title_sort | gene expression profiling identifies irf4 associated molecular signatures in hematological malignancies |
| url | http://europepmc.org/articles/PMC4160201?pdf=render |
| work_keys_str_mv | AT lingwang geneexpressionprofilingidentifiesirf4associatedmolecularsignaturesinhematologicalmalignancies AT zhiqyao geneexpressionprofilingidentifiesirf4associatedmolecularsignaturesinhematologicalmalignancies AT jonathanpmoorman geneexpressionprofilingidentifiesirf4associatedmolecularsignaturesinhematologicalmalignancies AT yanjixu geneexpressionprofilingidentifiesirf4associatedmolecularsignaturesinhematologicalmalignancies AT shunbinning geneexpressionprofilingidentifiesirf4associatedmolecularsignaturesinhematologicalmalignancies |